July 16, 2025 Kigali, Rwanda and San Francisco, USA

Bio Usawa, a company focused on producing life-saving, affordable monoclonal therapies for Africa and beyond, congratulates Professor Kwabena Frimpong-Manso Opuni, PhD on his appointment to Acting CEO of Ghana’s Food and Drugs Authority (FDA). Dr. Opuni comes to this position from a distinguished career spanning academia, public service, and pharmaceutical governance. He is recognized for his many contributions to Ghana’s health sector, where he most recently served as the Board Chair of the FDA, shaping regulatory policy and strengthening capacity development along with quality assurance frameworks. Throughout his career, he has focused on aligning regulatory systems with international standards in the areas of medicines and food safety.

"Having worked closely with Prof. Opuni, I’ve seen first-hand his deep commitment to strengthening regulatory systems and ensuring access to safe medicines. His leadership at the FDA will undoubtedly drive meaningful progress for public health in Ghana and beyond. Bio Usawa looks forward to continuing our partnership under his guidance,” remarked Mr. Eric Karikari-Boateng, Head of Global Regulatory Strategy at Bio Usawa.

Congratulations, Dr. Opuni!

About Bio Usawa, Inc. (BUI)

Bio Usawa has a singular mission: to manufacture and commercialize high-quality, effective and affordable biosimilars for patients in Africa. We are applying our 100+ years of combined experience in the industry in partnership with governments, agencies, educators and health professionals to make transformative biomedicines in Africa, by Africans, for Africans and beyond. 

Click here to learn more about our company's recent successes and download our new White Paper on Regulatory Approaches to Biosimilars in Africa.